Replay
Private Company
Total funding raised: $165M
Overview
Replay is an early-stage biotech developing next-generation gene therapies using its proprietary HSV vector platform, which is capable of delivering payloads up to 30 times larger than standard AAV vectors. This addresses a critical unmet need, as approximately 83% of human genes are too large to be packaged into AAVs. The company is assembling a seasoned leadership team and is positioned to target a range of rare genetic disorders that have been intractable to existing gene therapy approaches. As a private, pre-revenue company, it is currently in the pre-clinical development stage.
Technology Platform
Engineered Herpes Simplex Virus (HSV) vectors for gene therapy, capable of delivering DNA payloads up to 150kb (30x larger than AAV).
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Replay competes with other companies developing large-capacity gene delivery systems, including those using lentiviral vectors, adenoviral vectors, and other engineered HSV platforms. It also faces indirect competition from companies advancing gene editing (e.g., CRISPR) with non-viral delivery methods and those working on AAV dual-vector or mini-gene strategies to circumvent cargo limits.